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Abstract
Background:  Comorbid psychopathology is an important predictor of poor outcome for many types of
treatments for back or neck pain. But it is unknown if this applies to the results of medial branch blocks (MBBs)
for chronic low back or neck pain, which involves injecting the medial branch of the dorsal ramus nerves that
innervate the facet joints. The objective of this study was to determine whether high levels of psychopathology
are predictive of pain relief after MBB injections in the lumbar or cervical spine.
Methods: This was a prospective cohort study. Consecutive patients in a pain medicine practice undergoing
MBBs of the lumbar or cervical facets with corticosteroids were recruited to participate. Subjects were selected
for a MBB based on operationalized selection criteria and the procedure was performed in a standardized manner.
Subjects completed the Brief Pain Inventory (BPI) and the Hospital Anxiety and Depression Scale (HADS) just
prior to the procedure and at one-month follow up. Scores on the HADS classified the subjects into three groups
based on psychiatric symptoms, which formed the primary predictor variable: Low, Moderate, or High levels of
psychopathology. The primary outcome measure was the percent improvement in average daily pain rating one-
month following an injection. Analysis of variance and chi-square were used to analyze the analgesia and functional
rating differences between groups, and to perform a responder analysis.
Results: Eighty six (86) subjects completed the study. The Low psychopathology group (n = 37) reported a mean
of 23% improvement in pain at one-month while the High psychopathology group (n = 29) reported a mean
worsening of -5.8% in pain (p < .001). Forty five percent (45%) of the Low group had at least 30% improvement
in pain versus 10% in the High group (p < .001). Using an analysis of covariance, no baseline demographic, social,
or medical variables were significant predictors of pain improvement, nor did they mitigate the effect of
psychopathology on the outcome.
Conclusion: Psychiatric comorbidity is associated with diminished pain relief after a MBB injection performed
with steroid at one-month follow-up. These findings illustrate the importance of assessing comorbid
psychopathology as part of a spine care evaluation.
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Background
Facet injections are among the most commonly per-
formed non-surgical procedures in the United States for
axial low back or neck pain, representing a range of tech-
niques and indications[1] Published reviews of insurance
claims data from the U.S. have been unable to determine
the frequency by which each injection technique is used
(intrarticular vs. MBB), whether they were performed for
diagnostic or therapeutic purposes, or what medications
were injected[1,2] It is likely that the entire spectrum of
indications, techniques, and medications are used with
significant frequency, although some have recommended
that certain approaches are preferable[3] While there is
heterogeneity in the manner in which they are being used,
identification of predictive factors in order to help deter-
mine success from these injections as a treatment for back
pain is needed.
There is little agreement on what factors predict a success-
ful outcome from facet injections and much depends on
how they are used: indication (diagnostic vs. therapeutic),
method (intrarticular vs. MBB), or medications (anes-
thetic only vs. steroid)[4] Low-volume intrarticular injec-
tions are more specific for diagnosing facet-mediated
pain, while MBBs are more useful in treating a wider range
of back or neck pain since they block other potential pain
generators such as the multifidus muscle and the interspi-
nales ligament[5,6] The diagnostic and therapeutic results
have been comparable between the two techniques (intra-
rticular vs. MBB),[7,8] and both are associated with signif-
icant rates of false positives and negatives[4] Some
clinicians have used the results of these blocks in deciding
whom to offer a radiofrequency lesioning (RFL) proce-
dure, which may confer longer benefit. This has been
reported in some controlled studies as an average of 50%
pain reduction lasting 6 months[9,10] Since an RFL of the
medial branch dorsal ramus nerve also denervates the
medial third of the multifidus muscle[11], there is a
rationale supporting the MBB method, either for thera-
peutic or prognostic reasons.
An initial controlled trial found little therapeutic efficacy
at six weeks for facet injections with corticosteroid[12] But
more recent systematic reviews conclude that there is
moderate evidence for significant benefit with either the
intrarticular or MBB facet block technique (at least 30%
pain relief at 3 months, Level III evidence)[13] In many of
these reviewed studies injectate volumes of 1–2 mls were
used, which then are likely to spread beyond the dorsal
ramus nerve to adjacent structures. Thus, even though
therapeutic MBBs with steroid are treatments that are not
specific to the facet joint, they may be useful in helping
patients with axial neck or back pain.
There is, however, great variability in the subjects'
responses to MBBs[13] Few predictive factors for success
have been noted consistently, except for positive SPECT
bone scan findings of facet disease[14] While earlier stud-
ies suggest that response to facet injections could be pre-
dicted by patient history and physical
examination,[15,16] subsequent work has shown that
neither history, physical exam, nor radiographic findings
(CT, MRI, or X-ray) can predict pain relief[4,17-21]
Because symptoms and anatomic findings are poorly pre-
dictive of results, it is difficult for clinicians to appropri-
ately select patients for MBB injections. Although MBBs
would not be indicated for everyone with axial pain,
overly stringent selection criteria for performing these
injections would likely exclude many who might other-
wise benefit from this treatment. Yet, subgroups of
responders in pain treatment studies of clinic populations
can be identified reliably utilizing prospective observa-
tional designs based on possible predictive factors and
applying operational inclusion criteria[22] This suggests
that in treatment studies of MBBs confounding factors
such as the lack of a clear physical diagnosis and the lack
of specificity of an MBB to block the facet joint can be mit-
igated. Further identification of appropriate selection cri-
teria for a MBB would allow for improved predictability of
outcome.
Psychiatric illness–most often marked by depression, anx-
iety, and personality pathology–has been shown to be a
significant predictor of treatment outcome for chronic
musculoskeletal pain,[23] regardless of whether it occurs
prior to or after developing chronic pain[24] Psychopa-
thology afflicts 50–75% of clinic populations of chronic
pain patients,[25,26] and those with a combination of
negative affective disorders (such as depression and anxi-
ety, which often occur together) are prone to the worst
outcomes[27] In an effort to examine the relationship
between psychiatric comorbidity and the diagnostic use of
facet injections, Manchikanti, et. al., [28] identified 100
chronic low back pain patients with and without somati-
zation, who underwent intrarticular facet injections with
local anesthetic only, using the double block method.
They reported that the rate of immediate pain relief and
positive response from two blocks was the same (42%)
whether a somatization disorder was present or not. How-
ever, the non-somatizers also had significant rates of
major depression and generalized anxiety disorder, and
78% of the entire study population had at least one major
psychiatric disorder. Also, the patients were only assessed
for immediate pain relief after the procedure and were not
followed. Furthermore, conscious sedation was used for
the procedures, which the authors have reported to be a
significant confounder of positive and negative
responses[29,30] Thus, while the Manchikanti et al., studyBMC Musculoskeletal Disorders 2009, 10:22 http://www.biomedcentral.com/1471-2474/10/22
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reported little relationship between psychopathology and
outcome from diagnostic facet injections, there were con-
founding factors in the study design that made the results
difficult to interpret and therapeutic benefit was not stud-
ied.
In sum, psychiatric comorbidity is a negative predictor of
treatment outcome in general for chronic musculoskeletal
pain and the relationship between facet injection results
and psychiatric illness is still unclear. The aim of this study
was to evaluate whether psychiatric comorbidity pre-
dicted the outcomes of MBBs for patients with axial back
or neck pain. We hypothesized that patients with high lev-
els of depression and anxiety symptoms would have a
diminished response to a therapeutic MBB compared with
those with little psychiatric comorbidity.
Methods
Design and setting
This was a prospective, observational cohort study done
in a single, large, urban, university-based pain manage-
ment center. After IRB approval from Brigham and
Women's Hospital, all patients undergoing lumbar or cer-
vical MBB injections were invited to participate. Data col-
lection consisted of questionnaire surveys and de-
identified medical records review. Seven physicians, all of
whom were board-certified in Pain Medicine and had
practiced together for at least 5 years, participated in this
study.
Inclusion criteria
After giving verbal consent, subjects were considered for
inclusion based on a decision by the treating physician to
perform an MBB either as an independent therapy or as a
prerequisite for a possible RFL. Patients were selected for
an MBB based on the physician's assessment, which
included: 1) obtaining a history of primarily chronic axial
neck or low back pain, with radiation of pain in a com-
mon pattern for facet syndrome,[31,32] 2) documenta-
tion of whether the patient had facet loading signs or
paraspinal tenderness,[33] and 3) a review of relevant
supporting radiographic studies suggesting facet arthrop-
athy (with the understanding that patients frequently
have mixed conditions such as concurrent disc disease or
spinal stenosis)[4] These operational criteria have been
criticized in making the difficult diagnosis of facet-medi-
ated pain[4] It was not our intention to use these common
criteria to diagnose whether our patients had facet syn-
drome. However, by applying certain selection criteria
uniformly, our study would be able to evaluate the results
of the intended procedure for a certain group of patients
with axial back pain.
Procedures
At the time of the initial evaluation a comprehensive treat-
ment plan was proposed, which may have included the
use of injections as well as multidisciplinary treatments of
medications, physical therapy, and behavioral medicine,
if indicated. The MBB procedure was performed at three or
four levels in the cervical or lumbar spine, using local
anesthetic at each level (1–2 mls of 0.5% lidocaine for
skin and subcutaneous infiltration) and without any seda-
tion. A 22 gauge spinal needle was then placed at each spi-
nal level using flourscopic guidance, so that each needle
was positioned at the junction of the transverse process
and the superior articular process for lumbar injections
and at the waist of the articular pillar for cervical injec-
tions. The injections consisted of methylprednisolone
(20–30 mg, .5–.75 mls) and 0.25% bupivacaine (.5 ml) at
each level, a total of 1.0–1.25 mls injectate volume per
level. Depending on the physician's assessment of the
patient's condition, injections were done unilaterally or
bilaterally at 3–4 spinal levels. In all cases a total of 120
mg of methylprednisolone was injected.
Data collection
All measures were administered before the procedure and
one-month afterwards. For patients who did not schedule
a one-month follow-up visit, the scales were mailed after
three weeks for them to complete and return. For those
who missed their one-month visit, the scales were mailed
to them that day.
Primary outcome
Percent improvement in average daily pain rating at one
month was calculated using item 5 (average daily pain rat-
ing, 0–10 scale) of the Brief Pain Inventory (BPI)[34] The
BPI is a 15 item questionnaire assessing pain location,
intensity, relief, and quality, as well as pain-related quality
of life, validated in cancer and non-cancer pain stud-
ies[35] The activity interference items, such as pain inter-
ference with activity, sleep, or work, have shown a high
correlation with other functional and quality of life meas-
ures, such as the SF-36[36]
Primary predictor of outcome
The overall level of combined depression and anxiety
symptoms (High, Moderate, or Low levels of psychopathol-
ogy) was the primary predictor. The treating physicians
were blinded to group assignment. Group assignment was
determined using the Hospital Anxiety and Depression
Scale (HADS),[37] which includes subscale scores for anx-
iety and depression. The HADS is a 14-item self-report
survey designed for populations with medical illness. It
does not include somatic symptoms, such as fatigue and
sleeplessness, which may otherwise be attributable to
physical illness. It has been validated in several medical
illness populations with a sensitivity and specificity ofBMC Musculoskeletal Disorders 2009, 10:22 http://www.biomedcentral.com/1471-2474/10/22
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.66–.97 for a DSM-IV major depression or generalized
anxiety disorder diagnosis[38] Using validated cutoff
points, those with anxiety or depression subscale symp-
tom scores of ≥ 9 were classified as having high anxiety or
depression respectively, which most likely reflects a
comorbid anxiety or depression disorder[38] Those with
anxiety or depression subscale scores ≤ 6 were classified as
having low anxiety or depression levels, i.e. those signifi-
cantly less likely to have a disorder. Moderate levels for
anxiety or depression were operationalized as including
all of the scores in between these cutoff points. Patients
were assigned to High, Moderate, or Low level of psychiatric
comorbidity based on the subscale scores of the HADS. To
be in the High group, scores had to be high on both the
depression and anxiety subscales (i.e., at least 9 on each,
HADS total score ≥ 18). To be in the Low group, scores had
to be low on both subscales (total score ≤ 12), and the
Moderate group was all others not meeting High or Low cri-
teria. This approach emphasizes the magnitude of differ-
ence in total negative affective symptoms between the Low
and High groups and has been used in previous studies by
the authors[23,39]
Sample size calculations
We used a sample size calculation for a comparison of
means of the primary outcome between the three groups.
With Type I error of 5%, we sought 80% power to detect a
30% difference in pain improvement between the Low
and High groups. This is considered a clinically meaning-
ful difference[40] Using data from a previous study per-
formed by the authors in a similar clinic population,[23]
we assumed an average baseline pain level of 6.1 and a
standard deviation of 1.4. We estimated that 80 subjects
would be required and recruitment stopped when approx-
imately 80 one-month follow-up surveys had been
returned.
Data Analysis
An analysis of variance (ANOVA) was used to characterize
the relationship between the primary predictor and out-
come. Chi-square analysis was used to perform a
responder's analysis of patients categorized as those with
1) at least 30% and 2) at least 20% improvement in pain.
Twenty percent improvement was evaluated to examine
whether the response trends were consistent between the
groups at various levels of improvement. Baseline demo-
graphic, social, and pain history variables were included
in an analysis of covariance (ANCOVA). The data used to
calculate sample size requirements[23] led us to antici-
pate that the High group would be less likely to be work-
ing or married, and more likely to be taking prescription
opioids. We also included as covariates which physician
performed the procedure and whether other treatments
were begun at the time of the initial evaluation (such as
non-opioid medications or physical therapy).
Results
One hundred sixty six (N = 166) subjects were recruited
and follow-up surveys were returned by 86 of 166 partici-
pants (52% response rate). No differences were found
between the survey responders and nonresponders on any
demographic, social, pain history, or psychiatric variables.
The demographic, social, psychiatric, and pain history
characteristics of those who had completed the 1-month
follow-up surveys are presented in Table 1. 29 of the sub-
jects (34%) were grouped as High psychopathology, 20 of
the subjects (23%) were in the Moderate psychopathology
group, and 37 (43%) were in the Low psychopathology
group. There was a significant correlation between levels
of depression and anxiety (Pearson correlation coefficient
= .64, p = .01). Of the survey responders, the High psycho-
pathology group (n = 29) had a significantly lower per-
centage working (53%) and a significantly higher
percentage (73%) taking prescription opioids (p < .05).
Figure 1 summarizes the results for the main outcome var-
iable, the percent improvement in average daily pain rat-
ing at one-month follow-up for each psychopathology
group. There were significant differences amongst the
groups (ANOVA, R2 = .17, p < .001), with the Low (23%
improvement) vs. High (-5.8% worsening) groups having
the most significant contrast between group comparison
(Tukey correction; p < 0.0001). None of the three groups
reported significant improvements in the pain interfer-
ence items of the BPI (activity change, sleep change, etc.)
at one month follow-up. Nor were there significant
changes in anxiety or depression ratings after one month.
Figures 2 and 3 display a responder analysis of the propor-
tion of each group with at least 20% or 30% improvement
in pain levels, and demonstrates more contrasts between
groups. For those with at least 30% improvement, the Low
psychiatric morbidity group had a significantly greater
percentage of patients with pain relief than either the Mod-
erate or High groups. When the criterion was set at 20%
improvement, the same trends were found.
ANCOVA was used to test whether specific covariates
altered the strength of the predictive relationship between
psychopathology level and the degree of pain improve-
ment from a MBB. First, separate univariate tests with per-
cent pain improvement as the outcome were run for each
of the baseline factors listed in Table 1, treating physician,
and concurrent treatments (e.g. medications). Only opi-
oid use was a significant predictor (associated with less
pain improvement, Beta = -14; p < 0.05) and was carried
over to the next stage of modeling. Psychopathology
group and opioid use were then both entered into the
model to test whether opioid use remained a significant
main effect, whether it mitigated the strength of psycho-BMC Musculoskeletal Disorders 2009, 10:22 http://www.biomedcentral.com/1471-2474/10/22
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pathology group as a primary predictor, and whether
there was a significant interaction between the two. Opi-
oid use was not found to be a significant predictor, nor
were the estimated marginal means for psychopathology
group altered by > 10% compared with the means in the
model with psychopathology group as the only predictor.
Psychopathology group remained as the only significant
predictor of outcome (F = 6.0, R2 = .18, p < 0.01), and no
significant interaction was found.
Discussion
This study examined the impact of psychiatric comorbid-
ity on the response to medial branch blocks for spinal
pain and demonstrated that patients with elevated levels
of depression and anxiety are less likely to have a positive
outcome after a MBB injection performed for axial low
back or neck pain. One month following a MBB, the High
psychopathology group reported a 5% increase in pain
from baseline, while the Low psychopathology group on
average reported a 23% improvement in pain intensity.
These differences are even more apparent in the responder
analysis, in which the Low group had 2 to 4 times the rate
of positive response (45–57%) than the High and Moder-
ate groups (10–25%). Neither group showed significant
improvements in function. The degree of improvement in
the Low group was less than what has been reported in
previous studies[13] We think this occurred primarily for
two reasons: 1) Many of the earlier studies were per-
formed in community-based pain clinics whose patients
tend to have less severe pain and a shorter duration of
pain, and thus are less likely to be refractory to treatment
than our patient sample from a tertiary care center. 2)
Some of the studies of facet injections using steroid did so
after a positive response to a facet injection with anes-
thetic only. Hence due to selection bias in some of the pre-
vious studies, the study populations are not directly
comparable to our subjects.
The Low and High psychopathology groups had clear con-
trasts in psychiatric symptoms, with levels in the High
group consistent with major depression or generalized
anxiety disorder diagnoses. Forty eight percent of the sam-
ple had either a high level of depression or anxiety. This is
consistent with previous samples from pain clinics report-
ing a prevalence of psychiatric comorbidity ranging from
40–80%[41]
There is mounting evidence from neuroimaging studies
that psychiatric overlay in chronic painful illnesses alters
pain processing in the "pain matrix" in the brain[42,43]
This may result in amplified pain perception (particularly,
the affective component), akin to neuropathic mecha-
nisms amplifying pain at the level of the spinal cord.
These studies support the view that comorbid psychiatric
illness may disrupt descending pan inhibition, whose sys-
tem originates in brain areas modulating pain and mood,
such as the insula and anterior cingulate gyrus[44] This
alteration in endogenous antinociceptive activity may
undermine the effectiveness of MBBs modulating pain
transmission at the spinal level. Alternatively, one should
Table 1: Demographics, Social, Psychiatric, and Pain History
Psychopathology Group (N = 86)
Variable Low (n = 37) Mod (n = 20) High (n = 29) Sig1
Age (mean, yrs.)(CI)4 64.0 (59.0–69.0) 56.4 (49.2–63.6) 58.7 (53.1–64.2) NS
Sex (% female) 59 76 63 NS
Work Status (% working)2 87 95 53 p = .003
WC/Lit (%yes)3 553 NS
Maritial Status (% married) 69 44 59 NS
Pain Duration (mean, yrs)(CI)4 6.1 (3.7–8.6) 7.9 (4.4–11.4) 7.1 (4.4–9.8) NS
Location (% low back) 82 90 93 NS
Previous Spine Surgery (% yes) 39 24 40 NS
Hx Smoking (% yes) 54 62 47 NS
Prescription Opioids (% yes) 36 33 73 p = .003
Baseline Pain Level (0–10)(CI)4 6.1 (5.6–6.7) 6.8 (6.0–7.5) 6.2 (5.6–6.8) NS
Facet Loading Signs (% yes) 38 35 22 NS
Paraspinal Tenderness (%yes) 44 47 48 NS
Depression Score (mean)(CI)4 4.6 (3.9–5.3) 7.7 (6.7–8.6) 11.6 (10.8–12.4) p = .0001
Anxiety Score (mean)(CI)4 4.8 (3.9–5.8) 8.3 (7.0–9.6) 13.2 (12.1–14.3) p = .0001
1 = Chi square and ANOVA analysis
2 = Working includes homemakers taking care of children and those retired
3 = Active workers' compensation or injury litigation case (unsettled)
4 = 95% Confidence Interval
NS = nonsignificantBMC Musculoskeletal Disorders 2009, 10:22 http://www.biomedcentral.com/1471-2474/10/22
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consider that adverse motivational/behavioral factors in
the High group undermined any analgesic benefit of the
MBB steroid injection.
These results suggest, however, that use of careful selec-
tion criteria may increase the likelihood that patients may
benefit from steroid MBB injections for axial back or neck
pain. Psychiatric assessment is an important component
of any comprehensive spine care evaluation or treat-
ment[45] The administration of the HADS was feasible in
our medical setting and practitioners may consider using
it as part of the initial evaluation, upon which a treatment
plan is constructed. We are not suggesting that high
depression or anxiety scores be used as exclusion criteria
for an MBB, if that is considered. Rather, high scores may
signal that a multidisciplinary treatment plan should
begin first and then an MBB may be considered if that
patient adapts better psychologically to their pain. This
hypothesis remains to be tested.
Furthermore, psychiatric comorbidity is easily identifiable
and inherently treatable in a medical setting, and the
majority of psychiatric care in the United States is success-
fully delivered by primary care physicians utilizing medi-
cations and/or psychotherapy[46] Even subthreshold
levels of depression or anxiety respond to medication
treatment,[47,48] suggesting that patients with moderate
psychopathology in this study can also be readily treated
by the spine care physician.
While high levels of depression and anxiety were found to
predict response to steroid MBB injections, just as interest-
ing is that no other psychosocial (e.g., work status) or
medical variables (e.g., opioid use) were found to have a
significant impact on outcome. Recently, Cohen and col-
leagues reported that paraspinal tenderness predicted a
positive response to RFL[49] The results of our study
could not confirm that physical exam findings predicted
response to a single-injection MBB procedure. Although
our results comport with the findings of other studies
associating psychological variables to results from chronic
spinal pain treatments,[50,51] replication of these results
is needed.
Psychopathology Group and Pain Improvement Figure 1
Psychopathology Group and Pain Improvement. 
**between group contrast, p = .0001; F = 8.7, Rsq = .17; 
Error bars: +/- 1 SE
Percentage of Patients in Each Group with 20% Improvement Figure 2
Percentage of Patients in Each Group with 20% 
Improvement. **between group contrast, p = .001BMC Musculoskeletal Disorders 2009, 10:22 http://www.biomedcentral.com/1471-2474/10/22
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This study included a heterogeneous group of back pain
patients, such as those with concurrent disc disease or spi-
nal stenosis, and a MBB has been used by some as an aid
to diagnose facet syndrome. Even though this study was
not designed to confirm a diagnosis, the selection criteria
for inclusion in the study made it less likely that these
patients had radicular pain due to nerve root involvement
or nonspecific low back or neck pain[4] Given the lack of
differences in physical exam findings between groups, it is
also unlikely that differences in spine pathology
accounted for the study findings amongst the psychopa-
thology groups. In sum, most probably the heterogeneity
in spine pathology was distributed equally amongst the
groups, and thus is less likely to be a significant con-
founder to our results.
Another goal of a MBB, other than to clarifying a diagno-
sis, is to identify suitable patients for RFL. Commonly this
is done by judging the short-term response to a MBB,
using techniques such as the double-block method to
reduce the incidence of false-positive responses. Since we
were most interested in the one-month outcome after a
therapeutic MBB with steroid in a group of uniformly
selected patients, we did not utilize the double-block tech-
nique to determine candidacy for RFL, although this pro-
cedure might be considered in future studies. The design
of this study did not offer the opportunity to evaluate the
potential outcome from RFL after a steroid MBB, although
future studies would be useful in determining whether
treatment of psychiatric comorbidity prior to or in con-
junction with doing an MBB would improve the response
rate to an RFL. Furthermore, we cannot determine
whether the positive results in the Low group were placebo
responses. But because the patients were treated with an
MBB without the physicians knowing which group they
were in, the nonspecific effects of treatment were mini-
mized and the incidence of false-positive responses to the
MBB procedure would likely be the same in our study
groups.
Several additional limitations of this study merit discus-
sion: First, we were able to follow-up only 52% of the par-
ticipants, and consequently, although not statistically
significant, selection bias may have influenced the results.
Next, unlike some previous studies, we did not focus on
whether response to a MBB was useful in diagnosing facet-
mediated pain. Rather, in a subtle yet salient departure,
we concentrated on whether psychiatric factors predicted
response to a therapeutic MBB with corticosteroid per-
formed in patients with axial neck or low back pain. This
is an equally relevant clinical issue, and as stated, this is a
common indication for a MBB. We may have obtained
different results had we designed the study as a diagnostic-
based study rather than a treatment-based study. And
lastly, we only collected 1-month follow-up data. It is pos-
sible that more frequent ratings over a longer period of
time could have given different results.
Conclusion
Despite these shortcomings, the results of this study sug-
gest that high levels of psychopathology have a negative
impact on MBB outcome. Importantly, no other medical
or psychosocial covariates affected this result. Future stud-
ies should examine whether these findings extend to those
undergoing RFL. It will also be fruitful to examine
whether appropriate treatment of anxiety and depression
in a group of patients with chronic pain improves the
results of MBB injections and other procedural therapies.
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